Grades 3 to 4 toxicity
Adverse event . | No. of patients with grades 3 to 4 toxicity (%) . |
|---|---|
| Induction phase, n = 202 | |
| Nonhematologic | |
| Overall | 19 (9.5) |
| Hypotension | 5 (2.5) |
| Asthenia | 8 (4.0) |
| Other | 13 (6.4) |
| Hematologic | |
| Anemia | 4 (2.0) |
| Leukocytopenia | 6 (3.0) |
| Neutropenia | 19 (9.4) |
| Thrombocytopenia | 8 (4.0) |
| Randomized phase, n = 151 | |
| Nonhematologic | |
| Arm A, no further treatment | 2 (3) |
| Arm B, prolonged treatment | 7 (10) |
| Hematologic | |
| Arm A, no further treatment | 13 (17) |
| Arm B, prolonged treatment | 13 (18) |
Adverse event . | No. of patients with grades 3 to 4 toxicity (%) . |
|---|---|
| Induction phase, n = 202 | |
| Nonhematologic | |
| Overall | 19 (9.5) |
| Hypotension | 5 (2.5) |
| Asthenia | 8 (4.0) |
| Other | 13 (6.4) |
| Hematologic | |
| Anemia | 4 (2.0) |
| Leukocytopenia | 6 (3.0) |
| Neutropenia | 19 (9.4) |
| Thrombocytopenia | 8 (4.0) |
| Randomized phase, n = 151 | |
| Nonhematologic | |
| Arm A, no further treatment | 2 (3) |
| Arm B, prolonged treatment | 7 (10) |
| Hematologic | |
| Arm A, no further treatment | 13 (17) |
| Arm B, prolonged treatment | 13 (18) |